Chairman & Chief Executive Officer
Josh Disbrow has been in the life sciences industry for over twenty three years across pharmaceuticals, diagnostics, and medical devices. Prior to co-founding Aytu BioScience, Josh was the Chief Operating Officer of Ampio Pharmaceuticals (NYSE MKT: AMPE) and co-founded and led the Luoxis Diagnostics subsidiary. Luoxis was merged into Aytu in April 2015 following Luoxis’ development of the technology behind the company’s MiOXSYS in vitro diagnostic platform. Prior to joining Ampio in 2012, he served as Vice President of Commercial Operations at Arbor Pharmaceuticals, a specialty pharmaceutical company.Read more...
Josh began as Arbor Pharmaceuticals’ second employee and oversaw the launch and subsequent growth of the company’s commercial operations. Josh led the commercial organization prior to the launch of the company’s first product, subsequently launching numerous products and scaling the team to over 150 people across sales, marketing, managed care, sales training, distribution, and national accounts. In less than four years, Arbor grew from a company without any product revenues to a company with net sales of over $120 million. Prior to joining Arbor, he was the Director of Marketing at LipoScience (NASDAQ: LPDX), a specialty cardiovascular in vitro diagnostic company. Previously, Josh was in sales leadership at Cyberonics (Now LivaNova plc, NASDAQ: LIVN), a medical device company commercializing implantable neuromodulation devices. Josh started his career as a sales representative at Glaxo Wellcome (now GlaxoSmithKline plc). Josh sits on the board of directors and is Chair of the Nominating and Governance Committee of Zynex, Inc. (NASDAQ: ZYXI), a medical device company focused on electrotherapy and pain management. He holds a Bachelor of Science in Management from North Carolina State University and a Master of Business Administration from Wake Forest University.
Chief Financial Officer
David Green has been in the life sciences industry for over twenty-five years in scientific, operating and financial advisory roles. Prior to joining Aytu BioScience, David was the Chief Accounting Officer of Intarcia Therapeutics, a biopharmaceutical company engaged in late stage clinical development, where he was involved in IPO readiness and some of the largest private financing transactions in history for a pre-commercial, venture funded, life science company.Read more...
David was Chief Financial Officer of Catheter Connections, a venture financed medical device company that was acquired by Merit Medical [NASDAQ: MMSI]; and CFO of Specialized Health Products International, a publicly traded medical device company that was acquired by C.R. Bard [NYSE: BCR].
Prior to his operating roles, David advised a broad range of life science companies on issues of corporate finance and the use of strategic transactions to accelerate growth as a Managing Director of Duff & Phelps and as a member of Ernst & Young’s Palo Alto Center for Strategic Transactions®. David began his career performing medical research after he received a Bachelor of Science in chemistry from the State University of New York. He holds a Masters of Business Administration in finance from the University of Rochester and is a registered CPA.
Executive Vice President, Corporate Development
Jarrett Disbrow is a seasoned pharmaceutical entrepreneur having been the founder of three pharmaceutical and life sciences companies over the past decade and broad industry experience spanning over twenty years.Read more...
Most recently and prior to forming Aytu BioScience in April 2015, Jarrett was the President & CEO of Vyrix Pharmaceuticals, a specialty pharmaceutical company focused on male sexual dysfunction. Mr. Disbrow’s first pharmaceutical start-up was Arbor Pharmaceuticals, a company focused initially on pediatrics. As the sole founder of Arbor, Jarrett was responsible for the vision, fundraising, start-up, strategy and growth of the company until the acquisition by an investor group in 2010. Prior to founding Arbor Pharmaceuticals, he was head of marketing for Accentia Biopharmaceuticals, Inc. Jarrett began his career with GlaxoWellcome (now GlaxoSmithKline plc) where he held various roles in sales and marketing. He received a BS in Business Management from North Carolina State University in Raleigh, NC.
Matthew V. Phillips
Executive Vice President, Commercial Operations
Matthew V. Phillips is a business leader and commercial executive who has held progressive leadership positions at numerous healthcare companies over his twenty-five-plus year career. Most recently, Matt served as the Chief Commercial Officer of Cerecor, Inc. (NASDAQ: CERC), where he led all aspects of commercial operations and built a profitable pediatric commercial business unit.Read more...
In Matt’s executive role at Cerecor, he reported to the Chief Executive Officer and Board of Directors and maintained responsibilities beyond leading the commercial team. His responsibilities also included business development, collaboration with research and development, leading product and company acquisition processes, and leading market development in preparation for commercialization of multiple orphan drug candidates.
Prior to Cerecor, Matt was the President and Chief Operating Officer of Zylera Pharmaceuticals, which was acquired by Cerecor in 2017. Matt ran all aspects of commercial operations at Zylera and built a high-performing, entrepreneurial commercial organization that experienced rapid growth during his tenure. Previous to joining Zylera, Matt served as Executive Director of Managed Markets and Corporate Accounts at Victory Pharmaceuticals, where he developed and oversaw all aspects of reimbursement, distribution, and government accounts.
Earlier in his pharmaceutical career, Matt was an integral member of the management teams at Dura Pharmaceuticals and Eisai, Inc. Matt began his career in the home health care industry where he held progressive positions in sales and sales management.